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Background Dual renin–angiotensin system (RAS) blockade, mostly by combining an angiotensin converting enzyme (ACE) inhibi-
tor with an angiotensin receptor blocker (ARB), is increasingly used in patients with hypertension and diabetes and/or
proteinuria and in those with resistant heart failure. However, in the zest of achieving greater nephroprotection and
cardioprotection, even patients with uncomplicated essential hypertension are not uncommonly treated with dual
RAS blockade.
Evidence In 2003 the COOPERATE trial, seemed to confirm that dual RAS blockade was beneficial and that proteinuria
reduction was synonymous with nephroprotection. This study had to be withdrawn recently attesting to the suspi-
cion that the data looked to good to be true. Moreover, the large prospective ONTARGET data argue against a
nephroprotective effect of dual RAS blockade and together with renal findings from ACCOMPLISH, cast doubt
on albuminuria/proteinuria being a reliable surrogate endpoint for renal outcome. Although in heart failure, dual
RAS blockade had some benefit without reducing mortality, there remains a distinct safety issue with regard to hyper-
kalemia and elevated creatinine. Neither in ischaemic heart disease nor in left ventricular hypertrophy had dual RAS
blockade any benefits when compared with single RAS blockade. Of note, the combination of an ACE inhibitor with
an ARB was recently shown to reduce the risk of dementia. All dual RAS blockade may be created equal and the
combination of valsartan with aliskiren, a direct renin inhibitor will be evaluated in diabetic patients in the prospective,
randomized ALTITUDE study.
Conclusions For the time being, given the adverse effects and lack of consistent survival benefits, the use of dual RAS blockade
should be avoided unless ironclad data emerge to the contrary.
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Background
The concept of dual renin–angiotensin system (RAS) blockade ori-
ginated from the elegant animal model created by Menard et al.1
purporting to show a ‘synergistic’ effect between angiotensin con-
verting enzyme (ACE) inhibitors and angiotensin receptor blockers
(ARBs). It was hoped that combining the two drug classes would
be a way to avoid the escape phenomenon2 occurring because
of incomplete blockade of the RAS with monotherapy of either
an ACE inhibitor or an ARB. Dual RAS blockade was promptly
accepted primarily by nephrologists while it remained less poplar
among practicing physicians and cardiologists in spite of the guide-
lines and evidence derived from some studies. The concept
seemed so logical and appealing that changes in surrogate
endpoints such as blood pressure, proteinuria, endothelial dysfunc-
tions became accepted as a free pass for this combination having
cardioprotective and nephroprotective effects. Despite a lack of
solid evidence on safety and efficacy dual RAS blockade found
entrance into several sets of recent guidelines.
Current use of dual RAS blockade
In a meta-analysis of 49 studies with more than 6000 patients, Kunz
et al.3 found ‘encouraging’ evidence that dual RAS blockade
reduced proteinuria by 20–25% more than either drug alone.
Thus, dual RAS blockade is most commonly used in patients
with hypertension and diabetes and/or proteinuria and also to a
lesser extent in those with resistant heart failure. However, even
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patients with uncomplicated essential hypertension were not
entirely able to escape this fashionable trend. In the USA more
than 200 000 patients are currently treated with dual RAS block-
ade.4 Among these, the combination of an ARB and an ACE inhibi-
tor is by far the most common (70%) though other combinations
such as two ACE inhibitors (15%), two ARBs (5%) and ACE inhibi-
tors or ARBs in combination with a direct renin inhibitor (8%) are
used as well. To us, the raison d’eˆtre of some of these combi-
nations is not entirely evident. Clearly, such a prescribing pattern
reflects a distinct need for education.
The COOPERATE study
In 2003 a randomized control trial of 336 patients with non-
diabetic renal disease (COOPERATE) showed that dual RAS inhi-
bition with trandolapril and losartan reduced the risk of primary
endpoint (time to doubling of serum creatinine or end stage
renal disease) by a stunning 60% compared with monotherapy.5
Not surprisingly, the COOPERATE study brought oil to the fire
of dual RAS blockade and became one of the Lancet’s most
widely quoted papers.6 It was argued that ‘differences in renal pro-
tection are probably due to the much larger anti-proteinuric effect
of dual blockade’7 and ‘one should not only apply dual RAS block-
ade as fixed dose titration for proteinuria—but specifically pursue
the lowest level of proteinuria by individual dose titration. . . .’7
After the seemingly ironclad evidence put forward by the
COOPERATE trial, many physicians accepted the dictum that pro-
teinuria reduction was synonymous with nephroprotection.
Surrogate endpoints terminology
and surrogate endpoint failure
The FDA has defined a surrogate endpoint, or ‘marker,’ as ‘a lab-
oratory measurement or physical sign that is used in therapeutic
trials as a substitute for a clinically meaningful endpoint that is a
direct measure of how a patient feels, functions, or survives and
is expected to predict the effect of the therapy’.8 This definition
implies that the surrogate endpoint is not of any value to the
patient per se.9 Unfortunately, surrogate endpoints such as micro-
albuminuria, left ventricular hypertrophy (LVH) and endothelial
function have become synonymous for most physicians with
outcome. Indeed, even reputable journals seem to be careless
about surrogate endpoint terminology. Based on the fact that
the urinary albumin to creatinine ratio was reduced in patients
who received aliskiren as compared with those receiving
placebo, Parving et al.,10 in the AVOID study, concluded that alis-
kiren may have ‘renoprotective’ effects that are independent of
its blood pressure. In contrast, Mauer et al.11 documented in the
same journal that the 5 year cumulative incidence of microalbumi-
nuria was almost three times higher with losartan than with
placebo (P, 0.01 by the log-rank test). To be consistent with
regard to this surrogate endpoint terminology, should we now
conclude that indeed losartan has ‘renodestructive’ properties?
Pharmaceutical companies and investigators alike seem to have a
tendency to use euphemistic terminology when dealing with the
soft science of surrogate endpoints.
ONTARGET, COOPERATE,
ACCOMPLISH
The halo of dual RAS inhibition was finally shattered by the findings
of the large ONTARGET study.12 Similarly to previous findings,
albuminuria was reduced with the combination of telmisartan
and ramipril compared with monotherapy. However, since there
was significantly more doubling of creatinine and dialysis in the
combination arm (despite less albuminuria), ONTARGET clearly
argued against a nephroprotective effect of dual RAS inhibition
and also casts doubt on the contention of albuminuria being a sur-
rogate endpoint for renal outcome. At the same time a ‘letter of
concern’ by Kunz et al.13 found a number of serious inconsistencies
in the COOPERATE study thereby casting some doubt on the
veracity of these data. Further attesting to the unreliability of albu-
minuria as a surrogate end point are recent findings in the
ACCOMPLISH study.14 Although albuminuria was reduced in
both treatment groups, the overall reduction was greater in the
benazepril plus hydrochlorothiazide group than in the benazepril
plus amlodipine group despite the fact that the amlodipine combi-
nation slowed progression of nephropathy to a greater extent.
Heart failure
Benefits of dual RAS blockade were not only thought to be present
in diabetic hypertensive patients but also in patients with
New York Heart Association function Class 3 or 4 of heart
failure. In CHARM, the addition of candesartan reduced all com-
ponents of the primary outcome, total number hospital admissions
for heart failure, but not all cause mortality.15 Of note, the study
was not powered to show a mortality reduction. With the addition
of an ARB a slight reduction in mortality of 11% (P ¼ 0.086) in
heart failure was only seen in the CHARM/added (Candesartan
in Heart Failure—Added Trial) study16 and not in the CHARM/
alternative (Candesartan in Heart Failure—Alternative Trial)
study17 or the ValHeft (Valsartan Heart Failure Trial) study.18 In
ValHeft, the bulk of the benefits occurred in ACE inhibitor intoler-
ant patients. In the few patients who received valsartan and an ACE
inhibitor the morbidity benefits were significant only in those on a
low ACEi dose.19
In the combined study of Young et al.20 candesartan, when
added in a prespecified subgroup with a low ejection fraction
(,40%) resulted, in almost twice as many patients, in a small
but significant all-cause mortality reduction with a hazard ratio of
0.88 (CI: 0.79–0.98). Little surprise that patients who were not
already receiving an ACEi responded to the addition of an ARB.
The mortality benefits of the candesartan addition in the combined
analysis were therefore mainly driven by the patients who were
ACEi intolerant (and therefore only received an ARB and not
dual RAS blockade).
Despite all of these caveats, the evidence seemed to be suffi-
cient for recommending dual RAS blockade in guidelines for
heart failure.21,22 However, to our way of thinking, the benefits
of dual RAS blockade in heart failure may not be quite as robust
as some would like them to be.
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A major concern in heart failure is the safety issue. In CHARM
hyperkalemia was almost five times more common, and elevated
creatinine occurred twice as much with dual RAS blockade than
with monotherapy. A recent meta-analysis in over 18 000 patients
with left ventricular dysfunction showed a significantly increased
risk of adverse events leading to the discontinuation of dual RAS
blockade compared with monotherapy.23 Thus, hypotension, wor-
sening of renal function and hyperkalemia were more common
with combination therapy than with ACE inhibitor therapy alone.
Similarly, Kuenzli et al.24 found no benefit of dual RAS blockade
compared with monotherapy but more hyperkalemia, renal dys-
function and hypotension in an analysis of RESOLVD,25 Val
Heft,18 CHARM-ADDED16 and VALIANT.26 Thus, given the
adverse effects and lack of consistent survival benefits, the
routine addition of an ARB to ACE inhibitor therapy in heart
failure patients should be reserved for selected patients who
remain symptomatic on monotherapy. Clearly, dual RAS blockade
requires strict monitoring of renal function and potassium and
monitoring symptoms and signs of hypotension.
Left ventricular hypertrophy
In a small experimental study, dual RAS inhibition improved ventri-
cular lusitropy without affecting cardiac fibrosis.27 Similarly, Grandi
et al.28 reported a ‘beneficial’ effect of dual RAS blockade on con-
centric (LVH) in hypertensive patients in a randomized controlled
study. However, in ONTARGET, the prevalence of (LVH) was very
similar to dual RAS blockade as with monotherapy despite the fact
that the blood pressure was lower throughout the study with dual
RAS blockade.29 In ALLAY the reduction in the LV mass with the
combination of losartan plus aliskiren was not significantly different
from that with losartan monotherapy, independent of blood
pressure lowering.30 Thus in neither ONTARGET nor ALLAY
did the surrogate endpoint (LVH) move in the expected direction
with dual RAS blockade. This lack of incremental LVH reduction
argues therefore, to some extent, against a cardioprotective
effect of dual RAS inhibition. However, as the LIFE study31
taught us, neither is LVH an infallible surrogate endpoint: although
a significantly greater reduction in LVH occurred in the losartan
arm than in the atenolol arm, the rate of myocardial infarction
(MI) if anything remained higher and the rate of heart failure was
not reduced with losartan.32,33
Ischaemic heart disease
Recently, Baker et al.34 assessed the risk–benefit ratio of RAS and
dual RAS inhibition in patients with stable ischaemic heart disease.
Angiotensin converting enzyme inhibitor therapy reduced the
relative risk for total mortality and MI but increased the risk for
syncope by 24% compared with placebo. The authors contrast
this with the ONTARGET study in which dual RAS blockade
neither reduced total mortality nor MI but significantly increased
the risk of hypotension and syncope compared with ACE inhi-
bitor therapy alone. Their conclusion was that dual RAS block-




Of interest is the recent study by Li et al.35 in 819 491 predomi-
nantly male patients aged 65 or more with cardiovascular disease
from the administrative database of the US Veteran Affairs. In
this prospective cohort analysis, dual RAS blockade compared
with ACEi monotherapy was associated with a reduced risk of inci-
dent dementia (0.54, 0.51–0.57) and admission to a nursing home
(0.33, 0.22–0.49). ARBs exhibited a dose–response as well as
additive effects in combination with ACEi. Thus, dual RAS blockade
may offer some health benefits to those with cognitive decline.
These data are provocative and should be considered as hypoth-
esis generating only—a hypothesis important enough though to
be thoroughly and expeditiously explored.
Not all dual RAS blockade
is created equal
Direct renin inhibitors
In the past year another class of RAS blocker has become available,
represented by aliskiren, a direct renin inhibitor.36 Thus, dual RAS
blockade can now be achieved by combining an ACE inhibitor with
an ARB, an ACE inhibitor with a direct renin inhibitor, or an ARB
with a direct renin inhibitor. Since ARBs and ACE inhibitors both
increase plasma renin activity and only partially block the RAS,
the argument has been put forward that the addition of a drug
class such as a direct renin inhibitor, which decreases plasma
renin activity, has the potential to be more beneficial than blockade
with either an ACE inhibitor or an ARB alone.37 In theory, this is an
attractive concept and certainly deserves to be scrutinized in
outcome studies. Indeed, in a thorough double-blind study of
1797 hypertensive patients, a further fall in BP of 4.4–2.5 mmHg
was seen when aliskiren was added to patients who were on
the maximal dose of valsartan.38 However, at least in patients
having suffered an acute MI, the addition of aliskiren to either an
ACEi or an ARB did not further protect against ventricular remo-
deling in the prospective randomized ASPIRE trial.39 Of note, in
ASPIRE there was significantly more hypotension and hyperkalemia
with dual RAS blockade than with the ACEi or the ARB alone. The
combination of valsartan with aliskiren will be thoroughly tested in
diabetic patients in the ALTITUDE study. Other randomized trials
are currently investigating the benefit of combining aliskiren with
ARBs or ACE inhibitors such as ATMOSPHERE and ASTRONAUT
in chronic and acute heart failure, respectively.
Aldosterone blockers
The addition of an aldosterone blocker, either spironolactone or
eplerenone, to an ACE inhibitor or an ARB has been examined
in a number of trials. Dual blockade with an aldosterone blocker
decreases proteinuria40 and LVH41 beyond what is achieved by
either component of the combinations alone. No study has com-
pared proteinuria reduction of dual blockade with an aldosterone
blocker with dual blockade of ACE inhibitor/ARB. In heart failure,
however, in sharp contrast with dual RAS blockade by ARB/ACE
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inhibitor, the RALES trial42 as well as more recently, EPHESUS43
showed that aldosterone blockers prolong survival, when added
to usual care, including ACE inhibitor therapy. Worsening of
renal function and hyperkalemia were also more common when
combining an aldosterone blocker with ACE inhibition and close
monitoring is warranted. Since close monitoring is mandatory in
these patients, the level of available evidence would favour addition
of an aldosterone blocker as the next step in heart failure on ACE
inhibitor therapy rather than an ARB. In two recent meta-analysis,
mortality was reduced by 25% (P, 0.00001) with the addition of
aldosterone blockade44 as opposed to no significance with dual
RAS blockade.45 Thus, the data in aggregate (and cost) seem to
favour the addition of aldosterone blockade over ARBs.
Conclusion
The Lancet has now retracted the COOPERATE study thereby
confirming the lingering suspicion that these findings looked too
good to be true.46 Hopefully this retraction, together with findings
from studies such as ONTARGET and ACCOMPLISH together
with the meta-analysis of Lakhdar et al.23 will convince practicing
physicians that dual RAS inhibition with an ARB and an ACE inhibi-
tor was a fad whose time has come and gone. The sobering data
evolving from studies with dual RAS blockade should remind us
that surrogate endpoint failure is not uncommon and that leapfrog-
ging from surrogate data cannot ultimately substitute for patient
exposure in clinical outcome studies.
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